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Hyaluronan and proximal tubular cell migration.
Background. The ubiquitous polysaccharide hyaluronan has
been associated with both acute renal injury and progressive
renal disease. The aim of this study was to examine the effect
of hyaluronan on proximal tubular cell migration.
Methods. The proximal tubular cell line, HK-2 cells, were
grown in monolayer culture, and cell migration following addi-
tion of hyaluronan characterized in an in vitro model of injury
that we have previously developed and characterized.
Results. Addition of well-defined preparations of exogenous
hyaluronan increased cell migration; however, optimum en-
hancement of migration was seen with hyaluronan of high
molecular weight. Activation of the mitogen-activated protein
kinase (MAPK) signaling cascade, as assessed by increased ex-
pression of the dually phosphorylated active form of MAPK,
could be demonstrated following addition of hyaluronan. This
was blocked by the addition of a specific antibody to the
hyaluronan receptor, CD44. Hyaluronan-dependent enhanced
migration was also abrogated by addition the CD44 blocking
antibody, and by inhibition of MAPK kinase (MEK) activity.
Generation of a denuded area also led to increased synthesis of
endogenous hyaluronan and activation of MAPK, and blockage
of either CD44 or MAPK activation inhibited proximal tubule
cell (PTC) migration and re-epithelialization under nonstimu-
lated conditions.
Conclusion. We have demonstrated that hyaluronan activa-
tion of the MAPK pathway through binding to its receptor
CD44, enhances proximal tubule cell (PTC) migration. In ad-
dition, the results suggest that mechanical injury of PTC stim-
ulated hyaluronan generation. These observations may have
implications for both recovery from acute tubular injury and
progressive renal fibrosis.
The importance of pathologic changes in the renal
cortical interstitium is now well recognized, suggesting
that interstitial fibrosis represents a crucial development
leading to progressive renal dysfunction [1–6]. With in-
creasing awareness of the importance of these pathologic
interstitial changes, interest has focused on the role of
cells, such as the epithelial cells of the proximal tubule
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(PTC) or the interstitial fibroblast, in the initiation of a
fibrotic response. We have demonstrated that PTC may
contribute to the pathogenesis of renal fibrosis directly
by alterations in the production of components of the
extracellular matrix and indirectly by the production of
profibrotic cytokines [7–11]. Hyaluronan is an ubiquitous
connective tissue polysaccharide, which in vivo is present
as a high molecular mass component of the extracellular
matrix. In addition to its role in providing cellular sup-
port, it is now known that under normal circumstances,
hyaluronan regulates cell-cell adhesion, migration, prolif-
eration, differentiation, and the movement of interstitial
fluid and macromolecules (reviewed in [12]). As a result,
it is likely to be an important contributor to, and a regula-
tor of, wound healing and tissue remodeling. In the nor-
mal kidney, hyaluronan is expressed in the interstitium
of the renal papilla only, and alteration in papillary inter-
stitial hyaluronan has been implicated in regulating renal
water handling by affecting physiochemical characteris-
tics of the papillary interstitial matrix and influencing the
interstitial hydrostatic pressure [13]. Increased glomeru-
lar production of hyaluronan has been implicated in the
pathogenesis of diabetic nephropathy [14, 15]. Although
hyaluronan is not a major constituent of the normal renal
corticointerstitium, it is known to be expressed around
PTC following renal injury caused by diverse diseases
[16–19]. Increased deposition of interstitial hyaluronan
has also been correlated with renal function in progres-
sive renal disease associated with IgA nephropathy [20].
These observations suggest that hyaluronan may be in-
volved in repair following tubular injury, and also in the
mechanisms, which underlie progressive fibrosis.
PTC migration is common to both tubular repair and
progressive renal fibrosis. More specifically following
tubular injury, recovery of renal function is accompanied
by and may be dependent on the restoration of PTC in-
tegrity and function. This process is dependent on cell
proliferation as well as numerous other events such as
the organized migration and rearrangement of cells along
a modified tubular basement. In terms of progressive fi-
brosis, the presence of myofibroblast in the renal intersti-
tium has been identified as one of the best predictors of
progression [21, 22] and furthermore there is increasing
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evidence that these cells derive at least in part through
transdifferentiation of PTC [23–26]. Although it is clear
that cytokines such as transforming growth factor-b1
(TGF-b1) are critical in regulation of PTC phenotype,
less is known regarding regulation of their migration, a
process that is essential for the “transdifferentiated” cells
to enter the interstitial compartment [27]. The aim of
the current study was therefore to examine the effects
of hyaluronan on PTC migration, and the mechanism by
which it mediated these effects.
METHODS
Cell culture and quantification of cell migration
HK-2 cells [human renal proximal tubular epithelial
cells immortalized by transduction with human papil-
loma virus (HPV) 16 E6/E7 genes [28]] were cultured in
Dulbeccco’s modified Eagle’s medium (DMEM)/Ham’s
F12 medium (Invitrogen Ltd., Paisley, UK) supple-
mented with 10% fetal calf serum (FCS) (Biological In-
dustries Ltd., Cumbernauld, UK), 2 lmol/L glutamine
(Life Technologies Ltd., Paisley, UK), 20 mmol/L Hepes
buffer (Gibco BRL, Paisley, UK), 5 lg/mL insulin,
5 lg/mL transferrin, and 5 ng/mL sodium selenite (Sigma,
Poole, UK). Cells were grown at 37◦C in 5% CO2 and
95% air. Fresh growth medium was added to cells ev-
ery 3 to 4 days until confluent, and serum deprived for
48 hours prior to experimental manipulation. All exper-
iments were performed under serum-free conditions. In
all aspects of cell biology that we have studied previously,
HK-2 cells respond in an identical fashion to primary
cultures of human proximal tubular cells [29–32]. Fur-
thermore, in contrast to malignant transformed cells [33],
HK-2 cells exhibit an antiproliferative and antimigratory
response to TGF-b1 [34].
They are, therefore, a good model from which general
conclusions can be drawn in terms of PTC biology. How-
ever, to confirm that PTC immortalization per se did not
affect migration responses, additional experiments were
performed using primary cultures of human renal prox-
imal tubular cells (HPTC) isolated and characterized as
previously described [35]. Cell migration was examined as
previously described [36, 37]. Briefly, a denuded area was
generated on quiescent cell monolayers of HK-2 cells or
HPTC by scratching with a sterile pipette tip. The mono-
layer was washed twice with phosphate-buffered saline
(PBS) (Gibco BRL) and then incubated with serum-free
medium, or serum-free medium to which hyaluronan,
prepared as described below, was added.
To quantify re-epithelialization, an intersecting area of
denuded cells was generated as described previously [36,
37], and closure of the denuded area monitored using
an Axiovert 100M inverted microscope fitted with a dig-
ital camera (ORCA-1394, Hamamatsu Photonics, K.K.
Hamamatsu, Japan.), and images of the denuded area
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Fig. 1. Molecular weight distribution of the hyaluronan samples of
each weight average molecular weight shown as determined by gel per-
meation chromatography coupled to an online multi angle laser light
scattering system. Each line represents the molecular weight distribu-
tion of a separate hyaluronan preparation from which the weight av-
erage molecular weight (molecular weight per gram of molecule) is
derived.
captured as a digitalized sequence. The rate of motility
of cells was calculated as the number of cells entering the
central denuded area. Cell number was expressed as cells
per mm2 of original denuded area. Cell proliferation in
cell culture monolayers was evaluated by incorporation
of bromodeoxyuridine (BrdU) (Sigma) into the DNA of
cells as previously described [37].
Preparation and characterization of hyaluronan
of defined molecular weight
Hyaluronan samples (Lot No. F1750762), in the form of
freeze dried white powder was kindly provided by Denki
Kagaku Kogyo, Kabushiki Kaisha, Japan. A solution of
0.15 mol/L NaCl was prepared using pathogen-free wa-
ter. The solution was autoclaved at 128◦C for 20 minutes
and subsequently used to prepare 0.1% (wt/vol) stock
solution of hyaluronan. Two portions (∼20 mL) of the
stock solution were introduced into a clean vial and son-
icated for 1 and 5 minutes, then autoclaved for 20 min-
utes at 128◦C. The third portion was only autoclaved for
20 minutes at 128◦C. Two milliliters of the respective sam-
ple was withdrawn using a sterile syringe. The final con-
centration was accurately measured using the carbazole
method [38].
The weight average molecular weight and molecular
weight distribution was determined using gel permeation
chromatography coupled to an online multiangle laser
light scattering system (GPC-MALLS) (Fig. 1). Full de-
tails of the GPC-MALLS system are given elsewhere [39].
For a polydisperse rod-like polymer such as hyaluronan,
the weight average molecular weight is defined by:
Mw = ciMi
where Mw is molecular weight, ci is the molar concentra-
tion, and Mi the molecular weight of each of the individual
molecules.
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Immunocytochemistry
Immunocytochemistry for examination of the focal ad-
hesion components and cytoskeleton organization was
performed on cells grown in 8-well glass chamber slides
(Nunc, Gibco/BRL Life Technologies, Ltd., Paisley, UK).
Cells were grown to confluence and stimulated under
serum-free conditions with low- (5.4 × 104) or high-
(2.0 × 106) molecular-weight hyaluronan for up to 5 days.
Culture medium was subsequently removed and the cell
monolayer washed with sterile PBS. Cells were fixed with
3.5% paraformaldehyde for 10 minutes at room temper-
ature, and permeabilized with 0.1% Tween in PBS for
5 minutes at room temperature. Following fixation, cells
were blocked with 1% bovine serum albumin (BSA) for
1 hour prior to a further washing step with PBS. Sub-
sequently, slides were incubated with the primary anti-
body, diluted in 1%BSA/PBS overnight at 4◦C. Finally,
cells were incubated with the appropriate fluorescein
isothiocyanate (FITC)-conjugated secondary antibody.
Specimens were then mounted and analyzed by confo-
cal laser scanning microscopy (TCS-40) (Leica Microsys-
tems, Cambridge, UK).
Antibodies (and working dilutions) used for immuno-
cytochemistry were purchased as follows: rabbit anti-
human b-catenin (Santa Cruz, Wiltshire, UK) (dilution
1:100); rabbit antihuman ZO-1 (Zymed Laboratories,
Ltd., CA, USA) (dilution 1:100); mouse antihuman pax-
illin (Zymed Laboratories Ltd.) (dilution 1:100); mouse
TRITC-conjugated phalloidin antibody (Sigma) (dilu-
tion 1:50); FITC-conjugated goat antirabbit (Sigma) (di-
lution 1:100); FITC-conjugated rabbit antimouse (Dako
Cytomation Ltd., Cambridgeshire, UK) (dilution 1:100);
and mouse monoclonal blocking antibody to CD44 (The
Binding Site, Birmingham, UK).
Western blot analysis
Association of focal adhesion components with the
actin cytoskeleton was indirectly assessed by examining
their triton solubility as previously described [40]. Briefly,
confluent monolayers were washed once with cold PBS,
scraped and rinsed into 5 mL cold PBS. After centrifu-
gation at 2500 rpm for 10 minutes, cells pellets were ex-
tracted in buffer (150 mmol/L NaCl, 50 mmol/L Tris-HCl,
0.01% NaN3, 2 mmol/L ethylenediaminetetraacetic acid
(EDTA), 1 mmol/L sodium orthovandadate, 10 lg/mL
leupeptin, and 25 lg/mL aprotinin) containing 1% Tri-
ton X-100 (TX buffer) for 30 minutes on ice. Samples
were centrifuged at 12,500 rpm for 30 minutes and then
the supernatant (Triton-soluble components, including
membrane and cytosolic fraction) was transferred to a
separate tube and kept at –70◦C until use. Western blot
analysis was subsequently performed by standard
methodologies. Proteins were visualized using enhanced
chemiluminescence (Amersham Pharmacia Biotech UK,
Ltd., Buckinghamshire, UK) according to the manufac-
turer’s instructions.
Antibodies (and working dilutions) used for Western
blot analysis were purchased as follows: goat antihuman
vinculin (Santa Cruz) (dilution 1:1000); mouse antihu-
man paxillin (Zymed Laboratories, Ltd.) (dilution 1:500);
horseradish peroxidase (HRP)-conjugated secondary an-
tibodies (Sigma) (dilution 1:10,000).
Detection of MAPK kinase (MEK) activation status
Confluent cell layers or cell layers in which a denuded
area had been generated were washed once with cold
PBS, scraped, and rinsed into 250 lL reducing buffer.
After boiling at 95◦C for 5 minutes, equal amounts of
samples were loaded onto 10% sodium dodecyl sulfate-
polyacrylamide gel electrophoresis (SDS-PAGE) and
subjected to Western blot analysis as described above
using an anti-active MAPK antibody (Promega, Madi-
son, WI, USA), which recognizes the dually phosphory-
lated active form of MAPK (p44/ERK1 and p42/ERK2)
(final dilution 1:5000). Total MAPK expression was de-
termined using an antitotal MAPK antibody (Sigma)
(dilution 1:5000).
Fluorescence-activated cell sorter analysis
Cell surface CD44 expression was examined in cells
stimulated by hyaluronan preparations of different
molecular weight. Following cell harvesting, each was
incubated with an anti-CD44 common region antibody
(Calibiochem, San Diego, CA, USA) for 30 minutes at
4◦C (antibody dilution 1:1000). FITC-labeled secondary
antibody (Sigma) (dilution 1:100) was then added for a
further 30 minutes at 4◦C. Cells were subsequently re-
suspended in FACS buffer (Dulbecco’s Ca2+/Mg2+ free
PBS, 5% BSA, 10 mmol/L EDTA, and 15 mmol/L sodium
azide). Data were collected using a Becton Dickinson
(Oxford, UK) FACSCalibur 4CaTM, and analyzed using
CellQuest ProTM software.
Quantification hyaluronan concentration
by migrating cells
Generation of a denuded area was carried out as
described previously [34, 37]. Forty-eight hours later,
hyaluronan concentration in the cell culture supernatant
was determined by an enzyme-linked binding protein
assay (hyaluronic acid; “Chugai” quantitative test kit;
Chugai Diagnostics, Tokyo, Japan). To ensure that equal
numbers of cells were studied in all experiments, total
cell protein was determined using a micro bicinchonicic
acid kit (Pierce-Wariner, Chester, UK). There were no
differences in cell protein in any experiments. All experi-
ments were performed using the same volume of medium;
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therefore, the hyaluronan results are expressed as an ab-
solute concentration of hyaluronan.
Statistical analysis
Statistical analysis was performed using the unpaired
Student t test, with a value of P < 0.05 considered to rep-
resent a significant difference. The data are presented as
means ± SD of number of experiments. For each indi-
vidual experiment the mean of duplicate determinations
was calculated.
RESULTS
Hyaluronan and re-epithelialization
Characterization of the monolayer scratch system has
been described previously [34, 37]. Following the gener-
ation of a denuded area, the progress of a typical experi-
ment, under serum-free conditions, is shown in Figure 2A
[i]. Under nonstimulated serum-free conditions, the de-
nuded area was repopulated in all control experiments
5 days following injury. Previous studies have demon-
strated that FCS accelerated the kinetics of closure [34,
37], addition of 0.1% FCS was therefore used as a pos-
itive control (Fig. 2A [iv]). Addition of hyaluronan (25
lg/mL) led to increased cell migration as compared to
the migration seen in control experiments in HPTC (Fig.
2B). Although both low- (molecular weight 5.4 × 104) and
high- (molecular weight 2.0 × 106) molecular-weight
preparations led to increased migration of cells, the
promigratory effect was significantly greater with the
higher-molecular-weight preparation at all time points
beyond 24 hours. A significant increase in migratory
cell number following addition of hyaluronan was seen
24 hours after addition of high-molecular-weight hyaluro-
nan. In contrast, a significant increase in cell migra-
tion in response to the low-molecular-weight preparation
was only seen 120 hours after its addition to scratched
monolayers.
For HK-2 cells both dose- and time-dependent effect
of hyaluronan on cell migration were studied (Fig. 3).
As with primary cultures at all time points, the promi-
gratory effects of hyaluronan were greatest with the
high-molecular-weight hyaluronan preparation (molec-
ular weight 2.0 × 106). For the high-molecular-weight
preparation a significant promigratory effect was seen
after 72 hours. For the low-molecular-weight prepara-
tion (molecular weight 5.4 × 104), significant stimula-
tion of cell migration was seen after 120 hours. For
both hyaluronan preparations, stimulation of cell mi-
gration was directly dependent on the concentration of
hyaluronan used. At all time points studied the greatest
stimulation of cell migration was seen at the highest con-
centration of hyaluronan used.
Using this system we have previously demonstrated
that re-epithelialization of the denuded area is not de-
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Fig. 2. Hyaluronan enhances re-epithelialization. (A) Phase contrast
microscopy of HK-2 cells migrating into the denuded area of the scratch
wound. Quiescent cell monolayers were injured by scratching with a
sterile pipette tip to generate an area denuded of cells. All images were
taken 48 hours following injury to demonstrate relative efficiency of re-
epithelialization under control serum-free conditions [i], following ad-
dition of 25 lg/mL of low-molecular-weight hyaluronan, 5.4 × 104 [ii] or
following addition of 25 lg/mL of high-molecular-weight hyaluronan,
2.0 × 106 [iii]. For comparison, 0.1% fetal calf serum (FCS) was used
as a positive control to stimulate increased migration [iv]. (B) Quantifi-
cation of wound closure following addition of 25 lg/mL of high- (2.0 ×
106) () or low-molecular-weight (5.4 × 104) () hyaluronan to primary
cultures/human renal proximal tubular cells (HPTC). In control experi-
ments () cells were incubated with serum-free medium alone. Conflu-
ent monolayers of HPTC were scratched as described in the Methods
section to produce an intersecting area denuded of cell. Subsequently,
the rate of cell migration under each of the experimental conditions
shown was assessed by directly counting the number of cells migrating
into the intersecting denuded area at each of the time points indicated.
The data are expressed as the number of cells per mm2 of denuded area.
Data represent the mean ± SD of four individual experiments. ∗P <
0.05; ∗∗P < 0.005.
pendent on cell proliferation but rather on cell migration
[34]. Furthermore, addition of hyaluronan to growth ar-
rested HK-2 cells did not influence cell proliferation in
the wounded monolayer system using BrdU labeling as a
marker of proliferating cells. Figure 4A to C demonstrates
little uptake of BrdU at the edge of the denuded area
for up to 96 hours. Moreover, there were no differences
in BrdU uptake under serum-free conditions (Fig. 4A),
or following addition of either low- (Fig. 4B) or high-
(Fig. 4C) molecular-weight hyaluronan under serum-free
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Fig. 3. Quantification of dose and time dependent wound closure fol-
lowing addition high-molecular-weight hyaluronan (2.0 × 106) (A) or
low-molecular-weight hyaluronan (5.4 × 104) (B). Confluent monolay-
ers of HK-2 cells were scratched as described in the Methods section
to produce an intersecting area denuded of cell. Subsequently, the rate
of cell migration was assessed by directly counting the number of cells
migrating into the intersecting denuded area at each of the time points
indicated following addition of hyaluronan at concentrations of 1 lg/mL
(), 10 lg/mL (), or 25 lg/mL (), or under control conditions ().
The data are expressed as the number of cells per mm2 of denuded area
and represent the mean ± SD of four individual experiments ∗P < 0.05,
stimulated vs. control.
Fig. 4. Immunostaining of HK-2 cells with mouse anti-
bromodeoxyuridine (BrdU) to demonstrate the proliferative
response to wounding under serum-free conditions, or following
addition of 25 lg/mL of either low-molecular-weight hyaluronan (5.4 ×
104) or high-molecular-weight hyaluronan (2 × 106). (A, B, and C)
Cells at the edge of the scratched area 96 hours after mechanical injury.
(D, E, and F) BrdU labeling of cells from the unaffected layer away
from the “scratched” edge.
conditions. This is in contrast to assessment of cell prolif-
eration away from the denuded area in which prominent
cell proliferation was seen (Fig. 4D to F). Uptake of BrdU
was, however, no different from control (Fig. 4D) follow-
ing addition of either low- (Fig. 4E) or high- (Fig. 4F)
molecular-weight hyaluronan.
Fig. 5. Hyaluronan does not affect cell-cell contact, focal adhesion for-
mation or F-actin cytoskeleton organization. Adherens junction and
tight junction organization was examined by immunocytochemical anal-
ysis of the expression of b-catenin (A, B, and C) and ZO-1 (D, E,
and F), respectively. Cells were stimulated with 25 lg/mL of either
low-molecular-weight hyaluronan (B and E) or high-molecular-weight
hyaluronan (C and F). After 48 hours, cells were fixed with 3.5%
paraformaldehyde, prior to visualization of b-catenin, ZO-1 as de-
scribed in the Methods section. In control experiments, cells were ex-
posed to serumfree medium only for 48 hours prior to fixation (A and
D). Focal adhesion formation and F-actin cytoskeleton organization
was examined in confluent monolayers of HK-2 cells were stimulated
with 25 lg/mL of high-molecular-weight hyaluronan (H and K) (2.0 ×
106) under serum-free conditions. Serum-free medium alone was added
in control experiments (G and J) and addition of recombinant trans-
forming growth factor-b1 (TGF-b1) (10 ng/mL) was used as the positive
control to demonstrate up-regulation of focal adhesion formation and
F-actin reorganization as previously described (I and L). After 48 hours,
cells were fixed with 3.5% paraformaldehyde, prior to visualization of
paxillin (G, H, and I) or filamentous actin (J, K, and L) as described in
the Methods section. One representative experiment of four individual
replicate experiments is shown.
Mechanism of accelerated epithelial cell migration
in response to hyaluronan
Our previous studies demonstrated modification of
HK-2 cell migration following addition of TGF-b1 or
sodium orthovanadate was associated with alteration
in cell-cell contact, focal adhesion plaque formation
and their association with the F-actin cytoskeleton, and
changes in b3 integrin expression [34]. Addition of
hyaluronan did not influence cell-cell contact as assessed
by visualization of the adherens junction component b-
catenin (Fig. 5A to C) nor the tight junction component
ZO-1 (Fig. 5D to F). Furthermore, hyaluronan prepara-
tions, regardless of their molecular weight, did not al-
ter the expression the focal adhesion component paxillin
(Fig. 5G to I), nor organization of the F-actin cytoskele-
ton (Fig. 5J to L), as assessed by immunocytochemistry.
We have previously demonstrated that monolayer scratch
wounding per se did not affect expression or distribution
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of focal adhesion components nor the organization of the
F-actin cytoskeleton [34].
Modulation of cell function by hyaluronan may be reg-
ulated by alterations of its cell surface binding and in-
ternalization, which is mediated by its principal receptor
CD44. Cell surface CD44 expression examined by flow
cytometry using an antibody to the common region of
CD44 was no different to control following stimulation
by hyaluronan (data not shown). However, cell migration
and re-epithelialization in response to addition of exoge-
nous hyaluronan was inhibited by the addition of a mon-
oclonal blocking antibody to human CD44 (Clone BU52)
(The Binding Site Ltd.) (Fig. 6). Addition of the blocking
antibody was effective at abrogation of the promigratory
effect of both the high (Fig. 6B) and the low (Fig. 6C)
hyaluronan preparations.
Previous studies have demonstrated that CD44 medi-
ated alteration in cell function may be associated with the
MAPK signaling cascade [41]. In our epithelial mono-
layer wounding system, cell migration following addition
of exogenous hyaluronan, either the high- (2.0 × 106) or
low- (5.4 × 104) molecular-weight hyaluronan prepara-
tion, was inhibited by the addition of the MEK inhibitor
PD98059 (Calbiochem) (Fig. 7B and C). Furthermore,
addition of hyaluronan led to activation of MAPK as
assessed by MAPK phosphorylation status (Fig. 8), and
hyaluronan-mediated activation of MEK was abrogated
by the addition of CD44 antibody (Fig. 8).
The role of endogenous hyaluronan
in re-epithelialization
Previous work has demonstrated that mechanical in-
jury of peritoneal mesothelial cells in vitro is associ-
ated with induction of hyaluronan synthesis [42]. In the
current study, utilizing HK-2 cells, a significant increase
in hyaluronan concentration in the cell culture super-
natant was seen 48 hours following monolayer wounding
(Fig. 9). This represented a twofold increase over the con-
trol value (control, 91.1 ± 43.5 ng/mL; scratch, 180.3 ±
72.4 ng/mL; N = 12; P < 0.05). Addition of an anti-CD44
antibody caused an inhibition of cell migration (Fig. 10A)
below that seen in the unstimulated controls following
the generation of a scratch. This could also mimicked by
the addition of the MEK inhibitor PD98059 (Fig. 10B).
In addition, activation of MEK could be demonstrated
following “scratching” of the epithelial monolayer, and
this was also inhibited by the addition of the anti-CD44
antibody (Fig. 11).
DISCUSSION
Hyaluronan has long been associated with alteration of
cell migration of cultured cells [43]. Furthermore, numer-
ous studies suggest that hyaluronan may be involved in
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Fig. 6. Inhibition of hyaluronan stimulated cell migration by blockade
of CD44. (A) Phase contrast microscopy of HK-2 cells migrating into the
denuded area of the scratch wound. Quiescent cell monolayers were in-
jured by scratching with a sterile pipette tip to generate an area denuded
of cells. All images have been taken 48 hours following injury to demon-
strate relative efficiency of re-epithelialization under control serum-free
conditions, following addition of 25 lg/mL of high-molecular-weight
hyaluronan (HMW-HA) (2.0 × 106) or following addition of high-
molecular-weight hyaluronan in the presence of a blocking antibody
to CD44 (HMW-HA + CD44Ab) (5 lg/mL). One representative ex-
periment of four replicates is shown. Quantification of wound closure
following addition of either high-molecular-weight hyaluronan (HMW-
HA) (2.0 × 106) (B) or low-molecular-weight hyaluronan (LMW-HA)
(5.4 × 104) (C) in the presence (•) and absence () of blocking antibody
to CD44 (5 lg/mL). In control experiments () cell migration was as-
sessed in the absence of hyaluronan or anti-CD44 antibody. Confluent
monolayers of HK-2 cells were wounded as described in the Methods
section to produce an intersecting area denuded of cell. Subsequently,
the rate of cell migration under each of the experimental conditions de-
scribed was assessed by directly counting the number of cells migrating
into the intersecting denuded area at each of the time points indicated.
The data are expressed as the number of cells per mm2 of denuded area
and represent the mean ± SD of four individual experiments. ∗P < 0.05;
∗∗P < 0.005, for hyaluronan stimulated ± anti CD44 antibody.
epithelial cancer cell migration and metastatic potential
[44, 45]. The increased expression of hyaluronan asso-
ciated with either tubular injury and progressive renal
fibrosis led us to postulate that it may also modu-
late PTC migration. We have previously described a
simple and reproducible model with which to investi-
gate PTC migration. Re-epithelialization in this model
occurred in the absence of proliferation at the lead-
ing edge, thus the model is ideally suited to examine
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Fig. 7. Hyaluronan-stimulated cell migration is abrogated by mitogen-
activated protein kinase (MAPK) inhibition. (A) Phase-contrast mi-
croscopy of HK-2 cells migrating into the denuded area of the scratch
wound. Quiescent cell monolayers were injured by scratching with a
sterile pipette tip to generate an area denuded of cells. All images have
been taken 48 hours following injury to demonstrate relative efficiency
of re-epithelialization under control serum-free conditions, following
addition of 25 lg/mL of high-molecular-weight hyaluronan (HMW-HA)
(2.0 × 106) or following addition of high-molecular-weight hyaluro-
nan in the presence of PD98059 (HMW-HA + PD98059) (10 lmol/L).
One representative experiment of four individual replicate experiments
is shown. Quantification of wound closure following addition of ei-
ther high-molecular-weight hyaluronan (HMW-HA) (2.0 × 106) (B)
or low-molecular-weight hyaluronan (LMW-HA) (5.4 × 104) (C) in the
presence (•) and absence () of PD98059 (10 lmol/L). In control ex-
periments () cell migration was assessed in the absence of hyaluronan
or PD98059. Confluent monolayers of HK-2 cells were scratched as de-
scribed in the Methods section to produce an intersecting area denuded
of cell. Subsequently, the rate of cell migration under each of the ex-
perimental conditions described was assessed by directly counting the
number of cells migrating into the intersecting denuded area at each
of the time points indicated. The data are expressed as the number
of cells per mm2 of denuded area, and represent the mean ± SD of
four individual experiments. ∗P < 0.005, for hyaluronan stimulated ±
PD98059.
factors regulating PTC migration [34]. In this study, we
have clearly demonstrated that, in vitro, hyaluronan pro-
motes PTC migration. Recent studies suggest that high-
molecular-weight hyaluronan and low-molecular-weight
hyaluronan oligosaccharides present different signals to
cells. In general, high-molecular-weight hyaluronan rep-
resents the normal homeostatic state whereas the gen-
eration of low-molecular-weight hyaluronan fragments
signals a disruption of the normal homeostatic environ-
Active MAP kinase
Total MAP kinase
LMW-HA
HMW-HA
CD44-AB
p44/ERK1
p42/ERK2
− − + + − −
− − − − + +
− + − + − +
Fig. 8. Hyaluronan induced activation of mitogen-actived protein
(MAP) kinase is inhibited by CD44 blockade. Confluent monolayers
of HK-2 cells were stimulated with 25 lg/mL of either low-molecular-
weight hyaluronan (LMW-HA) (5.4 × 104) or high-molecular-weight
hyaluronan (HMW-HA) (2.0 × 106) for 48 hours in the presence or
absence of anti CD44 antibody (CD44-AB) (5 lg/mL). In control ex-
periments, cells were exposed to serum-free medium alone. Whole cell
extracts subjected to sodium dodecyl sulfate-polyacrylamide gel elec-
trophoresis (SDS-PAGE) and Western blotting were probed with anti-
active MAP kinase antibody, which recognizes the dually phosphory-
lated active form of MAP kinase. The blot was reprobed with an an-
titotal MAP kinase antibody to ensure no change in the expression of
whole cell MAP kinase expression. One representative of three indi-
vidual experiments is shown.
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Fig. 9. Mechanical injury of the HK-2 cell monolayer increases
hyaluronan generation. Quiescent cell monolayers were injured by
scratching with a sterile pipette tip to generate an area denuded of cells.
After 48 hours cell supernatant samples were collected for quantitation
of hyaluronan concentration as described in the Methods section. The
data represent the mean ± SD of three separate experiments. ∗P < 0.05.
ment. Several workers have reported that hyaluronan-
oligosaccharides may stimulate gene expression and
protein synthesis of chemokines [46] and interstitial colla-
gens [47]. In contrast, high-molecular-weight hyaluronan
inhibits the “bioactivity” of TGF-b and stimulate the se-
cretion of tissue inhibitors of metalloproteinases [48, 49].
The data in the current study support the notion that PTC
response to hyaluronan is also related to its molecular
weight in that, although all preparations of hyaluronan
are promigratory, this effect was most pronounced with
the highest-molecular-weight form.
To date, little is known regarding the functional signifi-
cance of alterations in hyaluronan in the renal cortex and
how might these results relate to renal disease. From our
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Fig. 10. Re-epithelialization under serum-free conditions is inhibited
by CD44 blockade (A) or inhibition of mitogen-activated protein
(MAP) kinase (B). Confluent monolayers of HK-2 cells were scratched
as described in the Methods section to produce an intersecting area de-
nuded of cell. Subsequently, the rate of cell migration under serum-free
condition () was compared to the rate of cell migration either in the
presence of 5 lg/mL blocking antibody to CD44 () or in the presence
of 10 lmol/L PD98059 (). The data are expressed as the number of
cells per mm2 of denuded area, and represent the mean ± SD of four in-
dividual experiments. ∗P < 0.05, control vs. either anti-CD44 antibody
or PD98059.
Active MAP kinase
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Fig. 11. Mitogen-activated protein (MAP) kinase activation following
mechanical wounding is inhibited by blockade of CD44. Quiescent cell
monolayers were injured by scratching with a sterile pipette tip to gener-
ate an area denuded of cells either in the presence or absence of a block-
ing antibody to CD44 (5 lg/mL). After 48 hours, total cell lysates were
analyzed for both activated and total MAP kinase activity by Western
blot analysis as described in the Methods section. One representative
experiment of four individual replicate experiments is shown.
data, we speculate that the net effect on altered hyaluro-
nan generation in the kidney is dependent on the disease
context. For example, promigratory effects of hyaluronan
related to tubular injury, may suggest that it may be in-
volved in the post-mitotic remodeling phase of recovery
[16–19].
Following tubular injury such as that seen following re-
nal ischemia, restoration of functional integrity is depen-
dent on PTC proliferation followed by migration along
a modified tubular basement membrane. Although the
proliferative phase has been extensively studied [50–53],
very little is known regarding the phase of remodeling,
which precedes restoration of normal renal function. Al-
though the kidney exhibits a remarkable ability to recover
from acute ischemic injury, it is also clear that, following
severe ischemic injury, kidney function may not com-
pletely return to normal.
Furthermore, studies in rats have shown that incom-
plete recovery from acute injury may be followed by pro-
gressive renal injury [54–56]. Reports that impairment of
graft function immediately after transplantation is asso-
ciated with increased risk of late graft loss suggest that
a similar predisposition to progressive renal disease may
also occur in humans following severe ischemic injury [57,
58]. Increased expression of hyaluronan around injured
cortical tubules has recently been documented following
ischemic injury. This coupled to the promigratory effects
documented in this manuscript suggest that increased ex-
pression of hyaluronan in acute injury may be a mecha-
nisms to limit injury and facilitate restoration of function.
In contrast to the potential benefit of hyaluronan in
acute tubular injury, the promigratory effect would sug-
gest that in the context of chronic renal disease, that
hyaluronan may have detrimental, profibrotic effects. It is
now clear that one of the key events during interstitial fi-
brogenesis is the de novo activation of a-smooth muscle
actin (a-SMA)-positive myofibroblasts. These cells are
primarily responsible for interstitial matrix accumulation
and deposition in chronically diseased states. Resident a-
SMA–positive myofibroblasts are sparse in the corticoin-
terstitium of the normal kidney, although their number
correlates with the degree of fibrosis in progressive renal
diseases [21, 22, 59].
Myofibroblasts were traditionally presumed to origi-
nate from resident fibroblasts. Recent evidence suggests
that a small number of these cells migrate to the inter-
stitial space from bone marrow [60]. In addition, they
may also arise in large numbers from tubular epithelial
cells via epithelial to mesenchymal transdifferentiation
(EMT) [24, 61, 62]. This process involves acquisition a
fibroblastic phenotype, as assessed by the expression of
fibroblast specific markers in vitro and in vivo [24]. Tubu-
lar epithelial to myofibroblast transition is proposed to
be an orchestrated, highly regulated involving four key
steps: (1) loss of epithelial cell adhesion, (2) de novo ac-
quisition of fibroblastic markers and reorganization of the
actin cytoskeleton, (3) disruption of the tubular basement
membrane, and (4) enhanced cell migration [27]. The key
profibrotic cytokine TGF-b1 is a critical regulator of PTC
phenotype and function [25, 26, 63]. However, although
TGF-b1 is an important factor in regulating these pro-
cesses, it is likely that transdifferentiation is not solely
dependent on the generation of TGF-b1. For example,
for PTC to reside in the corticointerstitium, they need
to adopt a promigratory phenotype. Although TGF-b1
may be associated with a migratory phenotype in the con-
text of malignant/metastatic phenotype of epithelial cells
[64], addition of TGF-b1 to PTC by increasing the avid-
ity of cell-matrix interactions inhibited migration [34].
There is now increasing evidence that although TGF-b1 is
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central to the process, that multiple factors may coop-
eratively regulate epithelial-mesenchymal transition in
the kidney. It is interesting to speculate therefore that
increased TGF-b1 and hyaluronan seen in progressive
renal fibrosis [20] act cooperatively driving the fibrotic
process, at least in part, through facilitating PTC transd-
ifferentiation and the formation of an expanding popula-
tion of renal interstitial myofibroblasts.
Numerous different mechanisms could explain the ef-
fect of hyaluronan on PTC migration. First, hyaluronan
through its ability to bind water forms highly hydrated
channels within the extracellular matrix, which facilitate
migration [65]. A second possibility would involve mod-
ification of the cell’s interaction with the extracellular
matrix. Previously we have demonstrated that regula-
tion of PTC-matrix interactions mediate alterations in
cell migration following addition of the profibrotic cy-
tokine TGF-b1 [34]. Addition of TGF-b1 led to a marked
inhibition of cell migration, increased expression of pax-
illin and vinculin and their incorporation into dense focal
adhesion plaques. This was associated with increased as-
sociation of focal adhesion components with the F-actin
cytoskeleton.
There was also increased b3 integrin expression and
increased synthesis of the matrix component fibronectin.
The data in the current study, however, clearly demon-
strate that the mechanism by which hyaluronan modified
cell motility was unrelated to focal adhesion assembly. A
third possible mechanism by which cell migration may be
modified is by alteration of cell-cell adhesion. Ectopic ex-
pression of each of the three isoforms of hyaluronan syn-
thase (HAS1, HAS2, or HAS3) led to reduced cadherin-
mediated cell adhesion and reorganization of filamentous
actin [66]. This is, however, unlikely to be the mode of
action of exogenous hyaluronan in our experimental sys-
tem, as we were unable to demonstrate any alteration
in the expression of components of either adherens or
tight junctions. That loss of cell-cell contract per se does
not equate with enhanced PTC motility is consistent with
our previous work demonstrating association of adherens
and tight junction complex disassembly with the antimi-
gratory effect of TGF-b1 [34]. The fourth possible mecha-
nism, by which exogenous hyaluronan may enhance PTC
migration, is through its interaction with its transmem-
brane receptors such as CD44, which is the principal re-
ceptor for hyaluronan. In our experimental system, en-
hanced migration following addition of hyaluronan was
abrogated by the addition of antibodies to this receptor. A
variety of signaling pathways, including the MAPK/ERK
pathway, have been reported to associate with CD44, and
postulated to account for hyaluronan-CD44–mediated
alterations in cell migration [41, 67–71]. In the current
study, enhanced cell migration was also reduced by in-
hibition of MEK, suggesting that exogenous hyaluronan
through its interaction with CD44 resulted in the subse-
quent activation of the MAPK cascade and increased cell
migration. It is of note that CD44 seems to have a rela-
tively low affinity for hyaluronan, requiring clustering or
oligomerization of CD44 for down stream signaling [72].
The maximal promigratory effect of hyaluronan seen with
the highest-molecular-weight preparation in the current
study would therefore be consistent with this observation.
Our observation that addition of exogenous hyaluro-
nan enhanced re-epithelialization led us to examining the
regulation of hyaluronan in the same system and de-
termining whether endogenous hyaluronan may in an
autocrine manner also facilitate re-epithelialization of
the denuded area. It is clear that the effect of endoge-
nous hyaluronan on cell migration may be dependent
of the cellular background. Increased hyaluronan syn-
thesis mediated enhanced migration in melanoma cells
[73], mesothelioma cells [74], and keratinocytes [75].
In contrast increased hyaluronan generation following
HAS transfection, inhibited migration of CHO cells [76].
Wounding of the PTC cell monolayer in our experimen-
tal system increased hyaluronan generation, and also ac-
tivation of MEK kinase. Furthermore, as with addition
of exogenous hyaluronan, cell migration was inhibited to
control levels by either addition of antibodies to CD44,
or inhibition of the MAPK cascade. This suggests that
re-epithelialization is indeed related to autocrine activa-
tion of CD44 by hyaluronan, and is consistent with pre-
vious observations from our laboratory demonstrating
increased hyaluronan synthesis restricted to the wound
edge and cells entering the wound following mesothelial
cell “wounding” [42].
We therefore postulate that exogenous hyaluronan ac-
celerated re-epithelialization in our system by enhancing
signaling through this autocrine pathway. Overall, the re-
sults presented in this study demonstrate that hyaluro-
nan stimulates PTC migration through CD44-mediated
activation of MAPK. We suggest that the functional sig-
nificance of these findings is dependent on the disease
background such that altered hyaluronan in acute injury
may provide a protective mechanisms to limit renal in-
jury, while in the chronic setting, in combination with
other factors, hyaluronan may enhance transdifferenti-
ation and the fibrotic response by facilitating migration
of PTC into the renal interstitium.
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